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Abstract. Intrahepatic cholangiocarcinoma (ICC) is charac-
terized as a highly fatal tumor with poor prognosis because of
its strong progression, early invasion, widespread metastasis
and rich cancerous stroma. Although it is widely accepted
that fibroblasts facilitate stromal fibrosis and tumor progres-
sion, the mechanisms of the interaction between cancer cells
and activated fibroblasts have not been fully elucidated thus
far. In this study, we demonstrate the presence of angio-
tensin II (AngII) in ICC tissues and explore the interaction
between hepatic stellate cells (HSCs) and ICC cells as one
of the sources of stromal fibrosis and tumor progression
through the interaction of the AngII/AngII type 1 receptor
(AT-1) axis. The concentrations of AngII in ICC tissues were
significantly higher than those of HCC and normal liver. Two
human ICC cell lines (HuCCT-1, CCKS-1) and a human HSC
cell line (LI-90) expressed AT-1 mRNA and protein. The
proliferative activity of ICC cells and HSCs to which AngII
was added dose-dependently increased and AT-1 antagonist
inhibited the proliferative effects. HSCs to which AngII was
added showed a higher expression of ·-smooth muscle actin
(·-SMA, a marker of activated HSCs and myofibroblasts),
glial fibrillary acidic protein (GFAP, a specific marker of
HSCs) and collagen type I than control cells. AT-1 antagonist
also inhibited the activation and transformation of HSCs
stimulated by AngII. These findings suggested that locally
formed AngII in ICC tissues plays a role in the proliferation
and activation of ICC cells and HSCs expressing AT-1 as a
growth factor in autocrine and paracrine fashions. Our mecha-
nistic findings provide the first insight into an autocrine and
paracrine AngII-initiated signaling pathway that regulates
ICC proliferation and fibrosis.
Introduction
Although both hepatocellular carcinoma (HCC) and intra-
hepatic cholangiocarcinoma (ICC) are primary liver tumors,
the amount of collagen tissue in each tumor is completely
different. It is well known that the characteristics of ICC are
the hypovascularity and richness of cancerous stroma as
determined by diagnostic imaging compared with those of
HCC. Although it is widely accepted that fibroblasts facilitate
stromal fibrosis and tumor progression, the mechanisms and
origins of such activated fibroblasts have not been fully
elucidated until now (1).
Terada et al demonstrated that ICC tissues had a greater
tendency to highly express trypsinogen/trypsin and cathepsin
B and that no HCC tissues had any expression of trypsinogen
(2). Human pancreatic cancer cells expressed and secreted
pancreatic cationic-type trypsinogen in vitro, which is spon-
taneously converted into active trypsin at acidic pH (pH 4.5-
5.5), in contrast to anionic-type trypsinogen, which is not.
Cationic-type trypsinogen could increase the invasive ability
and cell proliferation of pancreatic cancer cells (3). In
previous reports, it was described that the high expression of
a specific G-protein-coupled receptor, protease-activated
receptor-2 (PAR-2), was observed in pancreatic cancer cells
and fibroblasts around tumor tissue (4,5). PAR-2 activated by
its agonists, including trypsin and tryptase, plays an
important role in promoting the proliferation of pancreatic
cancer (6).
Meanwhile, Arakawa et al (7) demonstrated that trypsin
generated angiotensin II (AngII) from human plasma protein
in the absence of angiotensin converting enzyme (ACE)
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at weakly acidic pH 7.0). Our previous report showed that
pancreatic cancer tissues had higher trypsinogen expression
and higher AngII concentrations than other solid tumors, such
as HCC and colorectal cancer (8). We demonstrated that
angiotensinogen in the blood was directly converted to AngII
and in vivo evidence suggested a renin-angiotensin system
(RAS)-independent cascade in pancreatic cancer tissues.
Locally formed AngII was thought to act on pre-existing
pancreatic arteries around the tumor, leading to the formation
of hypoperfusive regions, so-called hypovascular or avascular
regions. Some reports have described the expression of
specific G-protein-coupled receptor, AngII type 1 receptor
(AT-1), in cancer cells and the role of AngII/AT-1 axis in
cancer proliferation, as well as the influence of the environ-
ment surrounding cancer cells as a potent mitogen (9).
Meanwhile, it has been reported that pancreatic cancer
cells induce fibrosis by stimulating pancreatic stellate cells to
proliferate and synthesize matrix (11,12). Hepatic stellate
cells (HSCs) are well known as an important component of
the background liver associated with chronic liver diseases
and liver tumors. The proliferation and activation of HSCs
are the dominant events in liver injury, inflammation and
fibrosis that render the cells responsive to cytokines and
other local stimuli. Following liver injury or stimulation by
various attractants, including monocyte chemoattractant
protein (MCP)-1, transforming growth factor (TGF)-ß1,
vascular endothelial growth factor (VEGF) or AngII, HSCs
undergo a response known as activation, which is the transfor-
mation of quiescent cells into proliferative and fibrogenic
myofibroblasts (activated HSCs), thereby modulating
inflammatory cell infiltration and subsequent hepatic fibrosis
(13-16). HSCs are similar to pancreatic stellate cells and may
contribute to the desmoplastic reaction associated with
primary and metastatic liver tumors (17,18). Recently, Okabe
et al reported that HSCs may differentiate into myofibro-
blasts in the cancerous stroma of ICC tissues and promote
the invasiveness and cell proliferation of cancer cells on
coculturing with ICC cells in a paracrine fashion (19).
We hypothesize that activated HSCs are one of the
resources of stromal fibrosis especially in collagen-rich liver
tumors, such as ICC, which has a higher level of AngII
through the co-interaction between cancer cells and HSCs.
The aim of the present work was to investigate the presence
of a RAS-independent AngII-generating system in ICC
tissues and to clarify the role of AngII in ICC progression
in an autocrine fashion. The interaction between fibrosis-
associated cells and cancer cells may induce the charac-
teristic differences between collagen-poor HCC and
collagen-rich ICC, which have fundamental differences in
the amounts of tumor-derived trypsin and locally formed
AngII. The hypoperfusive and fibrotic environment may
make ICC tissues more malignant and resistant to various
therapies. We also explored the paracrine interaction
between ICC cells and HSCs in tumor fibrosis through the
AngII/AT-1 axis. 
Materials and methods
Human tissue samples. The current study included ten
specimens of primary ICC (well to poorly differentiated
adenocarcinoma) that were surgically resected between 1998
and 2009. The average age of ICC patients was 67 years
(range 50-84 years). All patients had stage I-IVB disease on
the basis of the general rules for the clinical and pathological
study of primary liver cancer (20). Histologically, normal
liver tissues were obtained from non-tumoral portions of
resected ICC specimens. In addition, 11 cases of HCC were
examined for comparative study.
Immediately following surgical removal, the tissue
samples were frozen in liquid nitrogen and stored at -80˚C
until the time of the assay for measuring AngII concentration.
For immunohistochemical examination, the materials employed
in this study, 20% formalin-fixed and paraffin-embedded
specimens, were retrieved from the surgical pathology files
of the Pathology Section of Kanazawa University Hospital
(School of Medicine, Kanazawa University, Kanazawa,
Japan).
Cell culture. Two human ICC cell lines [HuCCT-1, obtained
from the Cell Resource Center for Biochemical Research,
Tohoku University, Sendai, Japan (21) and CCKS-1, obtained
from the Department of Human Pathology, Kanazawa
University Graduate School of Medicine (22)], and a human
hepatic stellate cell line [LI-90, obtained from the Human
Science Cell Bank, Saitama, Japan (23)] were used. ICC cell
lines were maintained at 37˚C in a 5% CO2 incubator and
grown in RPMI-1640 medium supplemented with 2 mM
glutamine, 10% fetal bovine serum (FBS), 100 U/l penicillin
and 100 μg/ml streptomycin. LI-90 cell lines were main-
tained at 37˚C in a 5% CO2 incubator and grown in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 2 mM
glutamine, 10% FBS, 100 U/l penicillin and 100 μg/ml strep-
tomycin. 
Reagents and antibodies. AngII was used at concentrations of
1, 10, 100 or 1000 nM (9). An active compound, telmisartan,
which is a novel, long-acting, selective AT-1 receptor
antagonist, was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and used at concentrations of 100 and 1000 nM,
according to a previous report (24). Transforming growth
factor (TGF)-ß1 was purchased from Sigma-Aldrich and was
used at a concentration of 10 ng/ml, according to a previous
report (25). For primary antibodies, we obtained rabbit
polyclonal AT-1 antibody (Santa Cruz Biotechnology, CA,
USA), mouse monoclonal collagen type I antibody (Santa
Cruz), mouse monoclonal ·-smooth muscle actin (·-SMA)
antibody (Sigma-Aldrich), mouse monoclonal ß-actin anti-
body (Sigma-Aldrich) and rabbit polyclonal glial fibrillary
acidic protein (GFAP) antibody (Dako Cytomation, Glostrup,
Denmark).
Measurement of angiotensin II in tissues. The determination
of AngII content was performed as follows. Briefly, tissue
samples were homogenized at 4˚C in saline containing 0.1 N
HCl and 5% urinastatin. The homogenate was sedimented at
10,000 x g for 30 min at 4˚C, and the supernatant was used
for radioimmunoassay of AngII using the florisil method
(florisil absorption and elution with acetone-hydrochloric
acid solution) as described previously (26). This method is
more sensitive, specific and useful for routine clinical
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investigation. Parallel frozen tissue samples were homo-
genized in phosphate-buffered saline (PBS). 
Immunohistochemistry. The expression of AT-1 in ICC
specimens was examined immunohistochemically using each
primary antibody. To identify the antigen in the tissue,
deparaffinized sections were pretreated by autoclaving in
10% citric acid buffer (pH 8.0) at 120˚C for 15 min. After
pretreatment with protein block serum (Dako Cytomation,
Kyoto, Japan) for 10 min and in 2% skim milk for 20 min to
block non-specific reactions, the sections were incubated
with each primary antibody at 4˚C overnight. The Envision+
polymer solution (horseradish peroxidase, HRP, secondary
antibody, Dako Cytomation) was then applied for 1 h. The
reaction products were developed in 0.02% 3,3'-diamino-
benzidine tetrahydrochloride (DAB) solution containing
0.1% H2O2. The sections were then lightly counterstained
with hematoxylin. The slides were examined under a fluores-
cence microscope (Olympus, Tokyo, Japan). Specimens were
classified as positive when >10% of cancer cells were
stained.
Immunocytochemistry. The expressions of AT-1 in ICC cells
and AT-1, ·-SMA and GFAP in HSCs were examined
immunocytochemically using respective primary antibodies.
The suspensions of each cancer cell were seeded on Lab Tek
chamber slides (Nunc) and incubated for 24-48 h at 37˚C in a
humid atmosphere of 5% CO2/95% air. The coverslips with
cells were then fixed with methanol and acetone 1:1 (v/v).
After pretreatment with protein blocking serum for 10 min to
block non-specific binding, immunostaining was performed
using Envision+ System. Briefly, the slides were incubated
with each primary antibody (1:50) at 4˚C overnight. After
washing, the Envision+ polymer solution was applied for 1 h.
The reaction products were visualized via a DAB reaction.
The cells were then lightly counterstained with hematoxylin
and examined under a fluorescence microscope.
Western blot analysis. AT-1 was recovered from subcon-
fluent HuCCT-1, CCKS-1 and LI-90 cells, which were
harvested, washed in cold PBS and lysed in ice-cold lysis
buffer [10 mM PBS (pH 7.4), 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 5 mM EDTA] supplemented with
1% phenylmethylsulfonyl fluoride and a protease inhibitor
cocktail for 30 min at 4˚C. The lysate was sonicated and
centrifuged at 15,000 rpm for 30 min at 4˚C to remove debris,
and the protein concentration was measured using a BCA
Protein Assay Kit (Thermo Scientific, USA). Total protein
was measured using a spectrophotometer. Extracted protein
was used for Western blot analysis. In this analysis, 20 μg of
protein from each sample was loaded onto 12.5% sodium
dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and the
proteins were transferred to a polyvinylidene difluoride
(PVDF) membrane by the semi-dry blotting method. The
membrane was washed for 10 min with blocking solution
(0.1% Tween-20; Ez Block, ATTO Corporation, Japan),
blocked at room temperature for 30 min with blocking
solution, and washed with washing solution (0.1% Tween-20,
Ez Wash; ATTO Corporation). The blots were incubated for
2 h at room temperature with each primary antibody against
AT-1 diluted at 1:500 with washing solution. The blots were
incubated for 1 h with an HRP-conjugated anti-mouse anti-
body (against anti-AT-1 antibody diluted at 1:5000 with
washing solution as a second antibody). Chemiluminescence
was detected with the ECL Plus Western blotting detection
system (GE Healthcare Bioscience, Japan) according to the
supplier's recommendations. We also used two antibodies,
·-SMA and GFAP, for Western blot analysis as fibrous
markers to measure the up- or down-regulation of the
expressions of ·-SMA and GFAP in LI-90 incubated in
medium with added AngII (100 nM) or TGF-ß1 (10 ng/ml).
Extraction of RNA and reverse transcriptase polymerase
chain reaction (RT-PCR) for AT-1 and GAPDH mRNA.
mRNA was isolated from HuCCT-1, CCKS-1 and LI-90 cell
lines using TRI Reagent (Sigma-Aldrich). Then, 1 μg of
mRNA was used to synthesize first-strand cDNA with an
RNeasy Mini Kit (Qiagen, USA) and QIA shredder (Qiagen),
according to the manufacturer's instructions. PCR for AT-1
and GAPDH was performed with a Taq Man PCR Kit
(Takara, Japan), according to the manufacturer's instructions.
The AT-1 forward primer sequence was 5'- TCAACAAAAAT
GAGCACGCTTT-3'; and the reverse was 5'-AAACATGGT
GCAGGCTTCTTG-3' (the pair generated a 485-bp fragment)
(27). The GAPDH oligonucleotide primer set (forward 5'-ACC
ACAGTCCATGCCATCAC-3', reverse 5'-TCCACCACCCT
GTTGCTGTA-3'; the pair generated a 452-bp fragment) was
used as an internal standard. PCR was performed for 35 cycles
(denaturation at 98˚C for 15 sec, annealing at 58˚C for 30 sec
and extension at 74˚C for 45 sec). After PCR, 5 μl samples of
the products were subjected to 2.0% agarose gel electropho-
resis and stained with ethidium bromide. 
Cell proliferation assay. The proliferative effect of AngII on
ICC and HSC cell lines was quantified using an MTT colori-
metric assay with Cell Proliferation Kit I (Roche), according
to the manufacturer's instructions. In brief, each cancer cell
line (5x103 cells/well) was grown in 96-well flat-bottom
microtiter plates in 100 μl of medium including 1% FBS and
incubated for 48-96 h at 37˚C in a humidified atmosphere
(e.g. 37˚C, 5% CO2). The medium contained different con-
centrations (1-1000 nM) of AngII or 10 ng/ml TGF-ß1. In
some experiments, telmisartan was added to AngII treatment
to make sure that the proliferative effect caused by AngII
occurred through the AT-1 receptor. After the incubation
period, 10 μl of the MTT labeling reagent (final concentration
0.5 mg/ml) was added to each well, the microplate was
incubated for 4 h in a humidified atmosphere (e.g. 37˚C, 5%
CO2) and then 100 μl of the solubilization solution was
added to each well. We allowed the plate to stand overnight
in the incubator in a humidified atmosphere (e.g. 37˚C, 5%
CO2), then checked for complete solubilization of the purple
formazan crystals and measured the spectrophotometric
absorbance value of the samples using a microplate reader.
The wavelength to measure absorbance of the formazan
product is 595 nm. The experiments were repeated in tripli-
cate wells. Cell viability was calculated as follows: Cell
number (% of control) = (absorbance of experimental wells) /
(absorbance of control wells) x 100 (%).
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Fluorescent immunocytochemistry. LI-90 cells were grown
on Lab-Tek chamber slides to 40-60% confluence, serum-
deprived overnight (DMEM + 1% FBS) and then treated with
AngII (100 nM) or TGF-ß1 (10 ng/ml). In some experiments,
telmisartan (1000 nM) was added to AngII treatment to make
sure that the effect caused by AngII occurred through the
AngII/AT1 axis. After fixation with 3.7% formalin, cells
were blocked with protein blocking serum. Cells were
incubated with the primary antibodies (·-SMA and GFAP)
for 1 h at room temperature. Slides were then washed and
incubated with the appropriate Alexa Fluor 488 and 592 nm
phalloidin-conjugated (Molecular Probes Inc., Eugene, OR)
specific secondary antibodies for double staining for 1 h at
room temperature. Cells were then incubated with Hoechst
33258 for nuclear staining for 5 min and mounted with propyl
gallate containing phenylenediamine under glass coverslips.
Cells were then visualized for immunofluorescence with a
laser scanning Olympus microscope at x10, x20 and x40
magnification.
Statistical analysis. Statistical analyses were carried out
using an unpaired t-test except for the measurement of AngII
concentration in tissues. In the measurement of AngII
concentration in tissues, analysis was carried out using the
Mann-Whitney U test. P<0.05 was considered significant.
Results
Angiotensin II concentration in tissues. Tissue AngII
concentration was determined radioimmunologically in tissue
extracts of ICC (n=10), HCC (n=11) and normal liver (n=5).
The concentration was 908±1167 pg/g wet tissue in ICC,
244±111 pg/g wet tissue in HCC and 162±107 pg/g wet
tissue in normal liver. Thus, AngII concentrations in ICC
tissues were significantly higher than those of HCC and
normal liver (Fig. 1). 
Immunohistochemistry and immunocytochemistry. Immuno-
histochemistry for AT-1 was expressed in 14 of 16 (87.5%)
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Figure 1. AngII concentration in tissue extracts of ICC, HCC and normal liver.
AngII concentrations in ICC tissues were significantly higher than those of
HCC and normal liver. *P<0.05.
Figure 2. Expression of AT-1 in ICC tissues. AT-1 receptor immunoreactivity was evident in membranous and granular cytoplasmic patterns and was predo-
minantly expressed in the center of the tumor. In addition, vascular endothelium, smooth muscle cells, fibroblasts and tumor-associated macrophages were
strongly positive for AT-1 receptor.
Figure 3. Immunocytochemistry for AT-1 in ICC cells and HSCs. (A, HuCCT-1; B, CCKS-1; C, LI-90) AT-1 expression was intense in HuCCT-1, CCKS-1
and LI-90 cells. AT-1 receptor immunoreactivity was evident in membranous and granular cytoplasmic patterns.
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surgical specimens of human ICC. AT-1 receptor immunore-
activity was evident in membranous and granular cytoplasmic
patterns and was predominantly expressed in the center of the
tumor (Fig. 2). In addition, vascular endothelium, smooth
muscle cells, fibroblasts and tumor-associated macrophages
were strongly positive for AT-1 receptor. In immunocyto-
chemistry, AT-1 expression was intense in HuCCT-1, CCKS-1
and LI-90 cells. AT-1 receptor immunoreactivity was evident
in membranous and granular cytoplasmic patterns (Fig. 3).
RT-PCR and Western blot analysis of AT-1 in human ICC
and HSC cells. AT-1 expression at the mRNA level was
detected in HuCCT-1, CCKS-1 and LI-90 cells (485 bp,
Fig. 4A). Western blot analysis also demonstrated AT-1
protein expression in all three cells (43 kDa) and AT-1 protein
expression mirrored that of mRNA (Fig. 4B).
Effect of angiotensin II on ICC and HSC cell proliferation.
To examine the effect of AngII, AT-1 receptor agonist, on the
proliferation of ICC and HSC cells, HuCCT-1, CCKS-1 and
LI-90 were treated with AngII or TGF-ß1 and the prolife-
rative effects were quantified by MTT assay. After incuba-
tion for 48 h, cell proliferation was significantly and dose-
dependently increased by AngII at concentrations from 1 to
1000 nM in HuCCT-1 and CCKS-1 cells (Fig. 5). In addition,
we determined whether the AngII-induced proliferative
response was inhibited by a specific AT-1 receptor antagonist,
telmisartan. Telmisartan significantly inhibited the 100 nM
AngII-induced proliferative response at a concentration of
1000 nM in both HuCCT-1 and CCKS-1 cells (Fig. 6). A
decrease in proliferation was not observed in the telmisartan
alone group compared with that of the control cells (vehicle-
treated cells). Therefore, these results demonstrate that the
suppressive effect of telmisartan on cell growth resulted from
the inhibition of AngII as a specific AT-1 receptor antagonist.
In LI-90 cells with each concentration of AngII, cell
numbers dose-dependently increased at concentrations from
1 to 100 nM. Telmisartan significantly inhibited the 100 nM
AngII-induced proliferative response at a concentration of
100 nM (Fig. 7).
Effect of AngII on activation and transformation in HSCs. It
has been reported that GFAP is expressed in quiescent or
partially activated HSCs and is known as a cell-specific marker
of HSCs. ·-SMA is also known as a cell-specific marker of
activated HSCs and myofibroblasts. HSCs transform into
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Figure 4. Expression of AT-1 mRNA and protein in ICC cells and HSCs.
AT-1 expression at the mRNA level was detected in HuCCT-1, CCKS-1
and LI-90 cells (A). Western blot analysis also demonstrated AT-1 protein
expression in all three cells types (B). Figure 6. Inhibitory effect of AT-1 antagonist, telmisartan, against prolifera-
ting ICC cells to which AngII was added. AngII-induced proliferative
response was significantly inhibited by 100 and 1000 nM telmisartan. A
decrease in proliferation was not observed in the telmisartan alone group
compared with that of vehicle-treated cells. Results are the means ± SD of
triplicate experiments. *P<0.05 versus 100 nM AngII.
Figure 5. Proliferative effects of AngII in ICC cells. ICC cells were treated
with different concentrations (1-1000 nM) of AngII, and their proliferative
effects were quantified by MTT assay. AngII induced a dose-dependent
increase in proliferative activity at concentrations of AngII from 10 to 1000 nM
for both HuCCT-1 and CCKS-1 cells. Results are the means ± SD of tripli-
cate experiments. *P<0.05 compared with control (untreated) cells by unpaired
t-test.
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myofibroblasts and the expression of ·-SMA in the cyto-
plasm of activated HSCs is enhanced when quiescent HSCs
are stimulated by attractants. In immunocytochemistry, the
expression of GFAP was ubiquitously found in the cytoplasm
of almost all HSCs, but the expression of ·-SMA was only
partially found in the cytoplasm of cultured HSCs. In
fluorescent immunocytochemistry, when LI-90 cells were
added to 100 nM AngII, the number of ·-SMA-positive LI-
90 cells was increased (Fig. 8). Telmisartan at 1000 nM
inhibited the activation of LI-90 cells and the transformation
to myofibroblasts cells. When 10 ng/ml TGF-ß1 was added
to LI-90 cells, the cells were activated and transformed into
myofibroblasts. In Western blot analysis, when LI-90 cells
were added to 100 nM AngII, the protein expression of ·-
SMA, GFAP and collagen type I significantly increased
(Fig. 9).
Discussion
Classically, RAS has been considered a hormonal circulating
system. This circulating RAS plays an important role in the
maintenance of blood pressure, electrolyte balance and fluid
homeostasis (28). Meanwhile, recent reports have suggested
that AngII is strongly associated with inflammatory diseases
and cancer progression in various organs (29-31). Locally
expressed tissue RAS components, including angiotensi-
nogen, renin and AngII receptors, may be involved in the
regulation of individual tissue functions, independent of
circulating RAS.
AT-1 activation by AngII is proposed to signal mitogen-
activated protein kinases (MAPKs), primarily via G proteins,
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Figure 7. Proliferative effects of AngII in HSCs. LI-90 cells treated with each
concentration of AngII (1-100 nM) dose-dependently increased in number at
concentrations of AngII from 10 to 100 nM. Telmisartan completely inhi-
bited the 100 nM AngII-induced proliferative response at a concentration of
100 nM. Results are the means ± SD of triplicate experiments. *P<0.05
versus control. **P<0.05 versus 100 nM AngII.
Figure 8. Fluorescent immunocytochemistry of AngII-induced activation and transformation of LI-90 cells (green, ·-SMA; blue, nuclei). When LI-90 cells
were added to AngII, the number of ·-SMA-positive cells increased (A, control cells; B, 100 nM AngII-treated cells). Telmisartan inhibited the activation of
cells (C, AngII 100 nM + Telmisartan 100 nM). Addition of 10 ng/ml TGF-ß1 also increased the number of ·-SMA-positive cells (D).
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in multiple ways. AT-1 activates focal adhesion kinase (FAK)
and this enzyme activates Src, Ras and Raf, which in turn
activate MAPKs resulting in the final activation of extracel-
lular signal-regulated kinase (ERK) that participates in the
phosphorylation of signal transducers and activators of
transcription (STATs). Phosphorylated STATs are translo-
cated to the nucleus, where they promote the transcription of
genes that participate in cell hypertrophy and hyperplasia, as
well as interferon-·, VEGF, fibroblast growth factor (FGFb),
platelet-derived growth factor (PDGF), Bcl-2 and Bcl-xL,
which block the caspase cascade, inhibiting apoptosis (30).
Nuclear factor-κB (NF-κB) plays a critical role in the regula-
tion of cell survival. NF-κB activation leads to anti-apoptosis-
related gene transcription including the inhibition of apop-
tosis protein (IAP) and Bcl-2 families, thereby providing a
survival-promoting signal and inhibiting cell apoptosis (32).
Survivin, a member of the IAP family, is expressed in the
most common cancer cells, and plays an important role
in resistance to radiotherapy (33,34). Amaya et al have
demonstrated that ERK1/2 and NF-κB activated by AngII
enhance the expression of anti-apoptotic proteins, including
survivin and Bcl-XL, and significantly prevent cancer cell
apoptosis in pancreatic cancer cells in vitro. Their study
suggested that AngII enhances cell proliferation and chemo-
resistance of cancer cells through the activation of ERK and
NF-κB via transactivation of epidermal growth factor (EGF)
receptor 9).
AngII is occasionally reported to be a stimulating factor in
HSC activation and the production of various cytokines and
chemokines. Activated HSCs to which AngII was added
promoted the production of TGF-ß and were an important
source of extracellular matrix (ECM) including collagens
(types I, III and IV), fibronectin, undulin, elastin, laminin,
hyaluronan and proteoglycans (13-16). We demonstrated that
the activation-dependent up-regulation of ·-SMA, GFAP and
collagen I expression occurred in LI-90 cells stimulated by
AngII. It was also demonstrated that AngII receptor blocker
(ARB) inhibited HSC proliferation, activation and transdif-
ferentiation into myofibroblasts. Our study specifically
addressed the in vitro behavior of HSCs to which AngII was
added; therefore, we monitored cell-specific markers for
HSC activation, namely, ·-SMA and GFAP. In liver tissue,
GFAP is expressed in quiescent or partially activated HSCs
but not in perivascular myofibroblasts. Therefore, the increased
expression levels of GFAP in AngII-treated cells reveal the
increase in the overall number of HSCs and can therefore be
utilized as a specific HSC proliferation marker. ·-SMA is
well known to be a marker for activated HSCs and myofibro-
blasts. The increased expression of ·-SMA, positive correlation
to collagen expression and the fibrosis-dependent enhanced
expression of ·-SMA emphasize the importance of HSCs in
AngII-induced activation (36,37).
Myofibroblasts can arise from activated HSCs, hepatocytes,
bone-marrow-derived cells and possibly endothelial cells.
Many studies suggest that myofibroblasts facilitate tumor
fibrosis, tumor growth and cancer progression (17-19,38-40).
The source of myofibroblasts and other activated fibroblasts
within tumors is still debated, but HSCs have become
recognized as one of the sources of cancerous stroma of liver
tumors.
Tumor progression and fibrosis are pivotal aspects of
malignant tumors, although their exact molecular mechanisms
with respect to tumor-stromal interactions remain to be
clarified. Several factors, including TGF-ß, hepatocyte
growth factor (HGF), EGF, VEGF, trypsinogen and AngII,
are regarded as candidate factors involved in cross-talk in
tumor-stromal interactions (9,10,38). Recent reports have
demonstrated the roles of stromal-cell-derived factor-1
(SDF-1) and its specific receptor, CXCR4, in tumor fibrosis
and cell proliferation, migration, survival and metastasis of
cancer cells (41-43). It has been demonstrated that SDF-1
released from stromal fibroblasts was responsible for the
migration of cancer cells expressing CXCR4. It has also been
reported that bone-marrow-derived fibroblasts can contri-
bute to the tumor stromal reaction and tissue fibrosis. This
suggests that bone marrow may be a source of tissue fibro-
blasts, which are one of the components of cancer-induced
stroma, and bone-marrow-derived activated fibroblasts were
recruited into cancer-induced stroma in late stages of cancer
(39). Carcinoma-associated fibroblasts (CAFs) are thought to
promote the growth of cancer cells, angiogenesis and stromal
fibrosis by recruiting endothelial progenitor cells through the
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Figure 9. LI-90 cells were incubated with 100 nM AngII. Representative Western blot results (A). Data are the mean ± SD of three independent experiments
(B). *P<0.05 versus control.
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interaction between SDF-1 secreted from CAFs and CXCR4
(40).
In conclusion, the present study demonstrated that ICC
tissues had high AngII concentrations and that this locally
formed AngII was associated with the tumor microenviron-
ment. The interaction between ICC cells and HSCs through
the AngII/AT-1 axis was suggested to have autocrine and
paracrine synergistic effects on tumor progression and cancer
fibrogenesis, and to make ICC highly malignant. A better
understanding of the interplay between ICC cells and
cancerous stroma will be important in developing strategies
for improved tumor therapy that take into account the
influence of the tumor microenvironment on tumor survival
and growth. Additionally, we showed that some important
effects of AngII antagonist are involved in tumor progression
and cancerous stroma in ICC tissues. Targeting the AngII
signaling pathway may not only affect the vascular dynamic
state in cancer tissues, but also be a novel, efficient strategy
for treating high-grade neoplasms with rich cancerous
stroma.
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